Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Exclusion Criteria

• •Ophthalmic:
• •Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles.
• •Intraocular pressure \>36 mmHg
• •Known hypersensitivity to any component of the formulation, latanoprost, or to topical anesthetics.
• •Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s)
• •Refractive surgery in study eye(s)
• •Ocular trauma within the six months prior to screening, or ocular surgery or laser treatment within the three months prior to screening.
• •Evidence of ocular infection and inflammation
• •Clinically significant ocular disease, which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe
• •Central corneal thickness greater then 600 μm
• •Any abnormality preventing reliable applanation tonometry of either eye
• •Systemic:
• •Clinically significant abnormalities (as determined by the investigator) in laboratory tests at screening.
• •Clinically significant systemic disease
• •Participation in any investigational study within 30 days prior to screening
• •Changes in systemic medication
• •Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.